Gracell Biotechnologies Inc.

NASDAQ GRCL

Data sourced from

and

Download Data

Gracell Biotechnologies Inc. Net Working Capital to Total Assets Ratio 3 year CAGR for the quarter ending September 30, 2023: 14.91%

Gracell Biotechnologies Inc. Net Working Capital to Total Assets Ratio 3 year CAGR is 14.91% for the quarter ending September 30, 2023, a 4,861.21% change year over year. The net working capital to total assets ratio measures the proportion of a company's net working capital (current assets minus current liabilities) to its total assets. It is calculated by dividing the net working capital by the total assets. This ratio indicates the percentage of a company's total assets that are financed by its net working capital. A higher ratio suggests a greater reliance on working capital to fund the company's operations and indicates a potential liquidity cushion. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Gracell Biotechnologies Inc. Net Working Capital to Total Assets Ratio for the quarter ending September 30, 2022 was 0.77, a -9.58% change year over year.
Gracell Biotechnologies Inc. Net Working Capital to Total Assets Ratio for the quarter ending September 30, 2021 was 0.86, a 58.94% change year over year.
Gracell Biotechnologies Inc. Net Working Capital to Total Assets Ratio for the quarter ending September 30, 2020 was 0.54, a -31.07% change year over year.
Gracell Biotechnologies Inc. Net Working Capital to Total Assets Ratio for the quarter ending June 30, 2019 was 0.78, a -3.68% change year over year.

NASDAQ: GRCL

Gracell Biotechnologies Inc.

CEO	Dr. Wei Cao
IPO Date	Jan. 8, 2021
Location	China
Headquarters	Building 12, Block B, Suzhou, China, 215123
Employees	314
Sector	Healthcare
Industry	Biotechnology

Description

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Key trends